Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2215850

N[C@@H]1C[C@H]1c1ccc(Br)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 16/20 0.67
MAOB P27338 10/20 0.67
KCNH2 Q12809 3/20 0.67
RCOR1 Q9UKL0 3/20 0.67
KDM1B Q8NB78 1/20 0.67
MAOA P21397 7/20 0.47
KDM4E B2RXH2 2/20 0.47
KDM6B O15054 1/20 0.47
KDM5C P41229 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM2A Q9Y2K7 1/20 0.47
KDM3A Q9Y4C1 1/20 0.47
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 4/20 0.46
CYP2B6 P20813 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2215848 1.00 KDM1A (0.67) KDM1AMAOBKCNH2RCOR1KDM1B
(+)-Tranylcypromine SCHEMBL15541916 0.84 MAOB (0.67) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL7865696 0.82 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL12242250 0.82 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL16019172 0.82 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL1524305 0.82 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL1524304 0.82 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL1667648 0.80 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL16340390 0.80 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL1667646 0.80 KDM1A (1.00) KDM1AMAOBKCNH2RCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1848695-B1 COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LTD (GB) 2011-07-27 EP disclosed
US-7790758-B2 glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives GLAXO GROUP LIMITED (GB) 2010-09-07 US disclosed
US-20080167351-A1 Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine GLAXO GROUP LIMITED (GB) 2008-07-10 US disclosed
EP-1848695-A1 COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-10-31 EP disclosed
WO-2006087169-A1 COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167351-A1 Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine GRIN1, GRM2, GRM1 KDM1A 3326/4885MAOB 1930/4885KCNH2 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.